サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747951

サブユニットワクチンの世界市場

Subunit Vaccines

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
サブユニットワクチンの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

サブユニットワクチンの世界市場は2030年までに23億米ドルに達する見込み

2024年に13億米ドルと推定されるサブユニットワクチンの世界市場は、2024年から2030年にかけてCAGR 10.1%で成長し、2030年には23億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるタンパク質抗原は、CAGR 11.2%を記録し、分析期間終了までに16億米ドルに達すると予想されます。多糖類抗原セグメントの成長率は、分析期間でCAGR 7.7％と推定されます。

米国市場は3億4,850万米ドルと推定、中国はCAGR13.9％で成長予測

米国のサブユニットワクチン市場は、2024年には3億4,850万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,960万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.1%と8.9%と予測されています。欧州では、ドイツがCAGR約8.0％で成長すると予測されています。

世界の「サブユニットワクチン」市場- 主要動向と促進要因のまとめ

サブユニットワクチンに対する世界の注目の高まりの原動力は？

近年、サブユニットワクチン市場は、より安全で標的を絞ったワクチン戦略への需要の高まりにより、現代免疫学において最も重要な分野の一つとして浮上しています。弱毒化または不活化された病原体を丸ごと使用する従来のワクチンとは異なり、サブユニットワクチンには免疫反応を刺激するのに必要な必須抗原のみが含まれており、副作用のリスクを大幅に軽減することができます。ワクチンの安全性に対する懸念が高まり、従来の予防接種法に対する市民の抵抗が高まる中、この特性はますます重要になってきています。COVID-19の大流行により、ワクチン・プラットフォームがかつてないほど注目されるようになり、その柔軟性、比較的早い製造サイクル、新たな亜種に対する変更の容易さにより、サブユニットワクチンが脚光を浴びるようになりました。世界の保健当局や政府は、特にHPV、B型肝炎、百日咳、そして最近ではCOVID-19などの疾病に対する予防接種戦略において、これらのワクチンに傾倒しています。さらに、サブユニットワクチンのスケーラビリティと安定性は、特にコールドチェーン要件が従来の製剤にとって大きなハードルとなる低資源環境において、ロジスティクス上の利点を提供します。

技術革新はワクチンデザインとデリバリーをどのように変えているのか？

分子生物学とタンパク質工学における最先端の進歩は、サブユニットワクチンの開発パイプラインに革命をもたらし、抗原の選択とアジュバントの組み合わせ戦略の改善につながりました。組換えDNA技術により、免疫優性抗原の正確な同定と合成が可能になり、得られるワクチンの特異性と有効性が著しく向上しました。AS04やMF59のようなアジュバント・システムは、免疫原性を高めるように進化しており、これにより、サブユニットワクチンの長年の課題のひとつである「最適でない免疫応答」を克服しています。さらに、ナノ粒子デリバリー・プラットフォーム、脂質ベース・キャリア、ウイルス様粒子（VLP）の統合により、抗原提示の改善と免疫の持続性に道が開かれました。研究機関や製薬会社はまた、バイオインフォマティクス・ツールや人工知能を活用して抗原の挙動をシミュレートし、候補の選択を最適化することで、研究開発期間を大幅に短縮しています。このような技術革新は、有効性を高めるだけでなく、人口統計や地域を超えてサブユニットワクチンの適用範囲を広げています。その結果、HIV、マラリア、結核などの複雑な病原体を標的とするワクチンの多様なパイプラインが現在臨床試験中であり、ワクチン設計のパラダイムが大きく転換していることを示しています。

政策と規制の転換は有利なエコシステムを醸成しているか？

サブユニットワクチン技術の急速な進化に対応するため、世界中の政策枠組みや規制状況は急速に適応しています。FDAやEMAのような規制機関は、特に公衆衛生上の緊急事態の際に、有望なワクチン候補のタイムリーな市場参入を確保するために、迅速な承認パスウェイとローリングレビュープロセスを導入しました。各国政府は、ワクチン研究インフラと製造能力の強化を目的として、いくつかの官民パートナーシップ、資金提供イニシアティブ、イノベーション・ハブを立ち上げています。こうした努力は、特にアジア太平洋やラテンアメリカなど、ワクチンの公平性が重要な政策課題となっている地域において、技術移転協定や国境を越えた共同研究が増加していることからも明らかです。さらに、世界保健機関（WHO）とGaviは、世界の予防接種アジェンダの中でサブユニットワクチンを重視し、サプライチェーンの優先順位付けと途上国への調達インセンティブを確保しています。さらに、非政府組織（NGO）や保健同盟の影響力が高まり、サブユニットワクチンを定期的な予防接種スケジュールに組み込むための協調的な取り組みが推進されています。これらの規制力学は、公的資金の増加や臨床試験プロトコルの調和と相まって、サブユニットワクチン市場における技術革新と迅速な商業化のための肥沃な土壌を作り出しています。

なぜサブユニットワクチンは今後急速に市場拡大するのか？

サブユニットワクチン市場の成長は、技術の進化、最終使用事例の拡大、消費者行動の変化に根ざしたいくつかの要因によって牽引されています。技術面では、抗原探索、タンパク質発現システム、組換え技術におけるブレークスルーが、ワクチン製造の精度とスケーラビリティを大幅に向上させています。さらに、予測免疫学と構造に基づくワクチン設計におけるAIの統合は、新興感染症に対する特異性の高い製剤の迅速な開発を可能にしています。最終用途の面では、特に免疫不全患者における安全性プロファイルが十分に立証されていることから、小児、成人、老年人口全体でサブユニットワクチンの採用が増加しています。病院や専門クリニックでは、予防医療にこれらのワクチンを取り入れる傾向が強まっており、これは国家的なワクチン接種プログラムや世界の健康義務化が拍車をかけているためです。消費者の認識も、パンデミック後にワクチンの安全性と有効性に対する意識が高まり、好意的に変化しています。北米や欧州のような先進地域だけでなく、新興国市場でも医療支出の増加やワクチン流通網の整備によって需要が急増しています。バイオ医薬品企業は、市場シェアを獲得するため、専用の製造設備への投資や戦略的合併によって対応しています。これらの要因を総合すると、世界の予防接種市場においてサブユニットワクチンが力強い成長軌道を描いていることがわかる。

セグメント

製品タイプ（タンパク質抗原、多糖類抗原）;疾患（感染症、ジフテリア／破傷風／百日咳、HPV、麻疹／おたふく風邪／風疹、その他の疾患）

調査対象企業の例（全 39件）

  • AIM Vaccine Co., Ltd.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Bharat Biotech
  • Bio Farma
  • BioNTech SE
  • Curevo Vaccine
  • ExpreS2ion Biotechnologies
  • GlaxoSmithKline plc（GSK）
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Medigen Vaccine Biologics
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India
  • Shantha Biotechnics
  • SK Bioscience
  • VBI Vaccines Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35835

Global Subunit Vaccines Market to Reach US$2.3 Billion by 2030

The global market for Subunit Vaccines estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 10.1% over the analysis period 2024-2030. Protein Antigen, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Polysaccharide Antigen segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$348.5 Million While China is Forecast to Grow at 13.9% CAGR

The Subunit Vaccines market in the U.S. is estimated at US$348.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$469.6 Million by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global “Subunit Vaccines” Market - Key Trends & Drivers Summarized

What Is Powering the Surge in Global Attention Toward Subunit Vaccines?

In recent years, the subunit vaccines market has emerged as one of the most critical segments of modern immunology, driven by a growing demand for safer, more targeted vaccination strategies. Unlike traditional vaccines that use whole pathogens-either weakened or inactivated-subunit vaccines contain only the essential antigens needed to stimulate an immune response, significantly reducing the risk of adverse effects. This characteristic has become increasingly vital amid rising concerns about vaccine safety and public resistance to conventional immunization methods. The COVID-19 pandemic brought unprecedented focus on vaccine platforms, propelling subunit vaccines into the spotlight due to their flexibility, relatively faster production cycles, and ease of modification for emerging variants. Global health authorities and governments have leaned towards these vaccines in their immunization strategies, particularly for diseases such as HPV, hepatitis B, pertussis, and more recently, COVID-19. Moreover, the scalability and stability of subunit vaccines offer logistical advantages, especially in low-resource settings where cold chain requirements pose a significant hurdle for traditional formulations.

How Is Technological Innovation Reshaping Vaccine Design and Delivery?

Cutting-edge advancements in molecular biology and protein engineering have revolutionized the development pipeline for subunit vaccines, leading to improved antigen selection and adjuvant pairing strategies. Recombinant DNA technology now allows for the precise identification and synthesis of immunodominant antigens, significantly enhancing the specificity and effectiveness of the resulting vaccines. Adjuvant systems like AS04 and MF59 have evolved to boost immunogenicity, thereby overcoming one of the longstanding challenges of subunit vaccines-suboptimal immune responses. Moreover, the integration of nanoparticle delivery platforms, lipid-based carriers, and virus-like particles (VLPs) has paved the way for improved antigen presentation and durability of immunity. Research institutions and pharmaceutical companies are also leveraging bioinformatics tools and artificial intelligence to simulate antigen behavior and optimize candidate selection, drastically reducing development timelines. These innovations not only increase efficacy but also broaden the applicability of subunit vaccines across demographics and geographies. As a result, a diverse pipeline of vaccines targeting complex pathogens such as HIV, malaria, and tuberculosis is currently in clinical trials, indicating a significant shift in vaccine design paradigms.

Are Policy and Regulatory Shifts Fostering a Favorable Ecosystem?

Policy frameworks and regulatory landscapes worldwide have adapted rapidly to accommodate the swift evolution of subunit vaccine technologies. Regulatory agencies like the FDA and EMA have implemented accelerated approval pathways and rolling review processes to ensure timely market access for promising vaccine candidates, especially during public health emergencies. Governments have launched several public-private partnerships, funding initiatives, and innovation hubs aimed at strengthening vaccine research infrastructure and manufacturing capacity. These efforts are evident in the rising number of technology transfer agreements and cross-border collaborations, particularly in regions like Asia-Pacific and Latin America, where vaccine equity has become a critical policy concern. Furthermore, the World Health Organization (WHO) and Gavi have emphasized subunit vaccines in global immunization agendas, ensuring supply chain prioritization and procurement incentives for developing nations. Additionally, the rising influence of non-governmental organizations (NGOs) and health alliances is driving coordinated efforts to integrate subunit vaccines into routine immunization schedules. These regulatory dynamics, coupled with increased public funding and harmonized clinical trial protocols, have created a fertile ground for innovation and rapid commercialization in the subunit vaccine market.

Why Are Subunit Vaccines Set for Rapid Market Expansion in the Coming Years?

The growth in the subunit vaccines market is driven by several factors rooted in technology evolution, expanding end-use cases, and shifting consumer behavior. On the technological front, breakthroughs in antigen discovery, protein expression systems, and recombinant technology are significantly enhancing the precision and scalability of vaccine production. Additionally, the integration of AI in predictive immunology and structure-based vaccine design is enabling the rapid development of highly specific formulations for emerging infectious diseases. On the end-use side, there is an increasing adoption of subunit vaccines across pediatric, adult, and geriatric populations due to their well-documented safety profile, especially in immunocompromised individuals. Hospitals and specialty clinics are increasingly including these vaccines in their preventive healthcare offerings, spurred by national vaccination programs and global health mandates. Consumer perception has also shifted favorably, with heightened awareness about vaccine safety and efficacy following the pandemic. Demand is surging not just in developed regions like North America and Europe but also in emerging markets, thanks to rising healthcare spending and improved vaccine distribution networks. Biopharmaceutical companies are responding by investing in dedicated manufacturing units and strategic mergers to capture market share. Collectively, these drivers underscore a robust growth trajectory for subunit vaccines in the global immunization landscape.

SCOPE OF STUDY:

The report analyzes the Subunit Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Protein Antigen, Polysaccharide Antigen); Disease (Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella, Other Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AIM Vaccine Co., Ltd.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Bharat Biotech
  • Bio Farma
  • BioNTech SE
  • Curevo Vaccine
  • ExpreS2ion Biotechnologies
  • GlaxoSmithKline plc (GSK)
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Medigen Vaccine Biologics
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India
  • Shantha Biotechnics
  • SK Bioscience
  • VBI Vaccines Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Subunit Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Shift Toward Safer Vaccine Platforms Propels Growth of Subunit Vaccine Market
    • Rising Incidence of Emerging Infectious Diseases Expands Addressable Market Opportunity
    • Increasing Public and Private R&D Investments Drives Innovation in Vaccine Delivery
    • Global Pandemic Preparedness Initiatives Strengthen Business Case for Scalable Vaccine Technologies
    • Advancements in Recombinant DNA Technology Spurs Development of Targeted Vaccines
    • Growing Focus on Personalized Vaccines Generates Demand for Subunit Formulations
    • Regulatory Push for Faster Approval Processes Supports Market Acceleration
    • Expansion of Pediatric and Geriatric Immunization Programs Sustains Market Growth
    • Greater Awareness of Vaccine Safety Drives Adoption of Subunit Vaccines
    • Increasing Partnerships Between Biotech and Pharma Drives Product Commercialization
    • Rising Demand for Thermostable Vaccines Enhances Development Efforts
    • WHO and GAVI-led Global Immunization Campaigns Drive Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Subunit Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Protein Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Protein Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Protein Antigen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polysaccharide Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polysaccharide Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polysaccharide Antigen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diphtheria / Tetanus / Pertussis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diphtheria / Tetanus / Pertussis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diphtheria / Tetanus / Pertussis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for HPV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Measles / Mumps / Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Measles / Mumps / Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Measles / Mumps / Rubella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • JAPAN
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • CHINA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • EUROPE
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Subunit Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • FRANCE
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • GERMANY
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Subunit Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • INDIA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Subunit Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Subunit Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • AFRICA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION